Ranbaxy Settles Imitrex Dispute with GlaxosmithKline

By Joseph Major
21 January 2008 @ 11:47 pm EDT

Indian pharmaceutical major Ranbaxy Laboratories Ltd said Monday that it reached a settlement with British drug maker GlaxoSmithKline over possible patent litigation regarding a generic version of Glaxo's Imitrex tablets.

Secret Service agents walk down the aisle as the campaign charter carrying Democratic presidential candidate, Sen. Barack Obama, D-Ill, lands in St. Louis, Mo., Monday, July 7, 2008. The airplane has made a safe, unscheduled landing in St. Louis Monday after a maintenance issue arose en route from Chicago to Charlotte, N.C. (AP Photo/Jae C. Hong)

1 of 1

The settlement allows Ranbaxy to distribute the generic version of the drug, Sumatriptan Succinate Tablets in the United States starting at the expected launch date in December 2008.

Ranbaxy will be allowed to distribute the generic drug in sizes of 25mg, 50mg and 100mg.

Other terms of the agreement were not disclosed.

Researcher IMS estimates that the market for Imitrex was $985 million as of September 2007.

Ranbaxy Settles Imitrex Dispute with GlaxosmithKline

Most Popular Slideshows

Most Popular on IBTimes